Boehringer leads the development of the corona drug

Frankfurt Pharmaceutical company Boehringer Ingelheim is leading the development of a drug for patients with Covid-19. A Phase 2 clinical trial is to be started with the active ingredient BI 764198, in which it is to be tested as a therapy in hospital patients with corona infection and severe respiratory complications, the second German pharmaceutical manufacturer after Bayer announced Wednesday.

The goal is that, thanks to the agent, it is possible to reduce the need for artificial ventilation and improve the recovery rate of patients. According to Boehringer Ingelheim, 67 to 85 percent of Covid 19 patients in an intensive care unit who suffer from acute respiratory distress syndrome could benefit.

Boehringer is currently researching a range of treatment options for Covid-19 lung disease caused by the new coronavirus. Human vaccines, however, are not at the heart of the company’s research.

More: Pharmaceutical companies want to provide worldwide access to Covid-19 vaccines and drugs